Trials / Withdrawn
WithdrawnNCT03992443
Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) Functionality
A Phase 3, Open Label, Single Arm Study on the Use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to evaluate the efficacy and safety of CUSA-081 in the restoration of central venous access device (CVAD) functionality in participants 12 years and older.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CUSA-081 | Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen |
Timeline
- Start date
- 2022-02-28
- Primary completion
- 2022-03-18
- Completion
- 2022-03-18
- First posted
- 2019-06-20
- Last updated
- 2022-04-15
Locations
15 sites across 3 countries: United States, Bulgaria, Hungary
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03992443. Inclusion in this directory is not an endorsement.